This Week in TB R&D – 24 August 2010

A distinct whole-blood 86-gene transcriptional signature of active TB (Figure 2 in the paper)

Last week, a paper was published in Nature by Matthew Berry, Christine Graham et al. which received a fair amount of notice. The authors presented data identifying a probable TB gene signature in people infected with TB.

Initially the investigators examined genome-wide transcriptional profiles generated from RNA extracted from whole blood, purified neutrophils, monocytes, and T cells collected from healthy controls, patients with active TB (before treatment), and patients with latent TB. They observed a 393-transcript signature in patients with active TB and confirmed the presence of this 393-transcript signature in active TB patients in two distinct patient cohorts (London, an intermediate TB burden region and South Africa, a high-burden TB region). Furthermore, the observance of the signature was independent of ethnicity, age, or gender.

Interestingly, 10-25% of latent TB patients also carried the 393-transcript signature, which correlates with the recognized conversion percentage of latent TB to active TB in the general population. Drug treatment of patients with active TB resulted in a decrease in the 393-transcript after 2 months, and the apparent loss of the transcript after 12 months of treatment.

To rule out that the 393-transcript was a general inflammatory response, the investigators used further genetic mining tools to identify a 86-gene signature. Genes from this signature were further correlated with the interferon-γ and type-1 interferon-inducible gene pathway.

While interferon signaling pathways play critical roles, data presented in this paper may lead to not only a rapid-point of care diagnostic tool, but identification of novel biomarkers for disease progression and/or surrogate endpoint biomarkers essential for clinical drug development testing.

Is a point-of-care diagnostic tool close at hand based on the data from this paper? Should the type-1 interferon-inducible signature be more closely favored for development of a point-of-care diagnostic than the interferon-γ signature? Why or why not? Would a TB blood assay be more advantageous for tracking TB treatment prognosis? What are your thoughts and comments? Please share them below.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...